Coronavirus Disease 2019 (COVID-19): Pathogenesis, Immune Responses, and Treatment Options

Main Article Content

Nandini Eswaran
Shwetha Krishna


Background: The emergence and the spread of the novel coronavirus or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating impact on the economy and has become a pressing issue globally. Due to the significant increase in the number of confirmed cases and death tolls worldwide, and certain countries reporting second waves, there is an immediate need for an effective vaccine or other therapeutic intervention to control the spread of the disease. Improving our understanding on the host’s anti-viral immune response on SARS-CoV-2 infection, the potential immune evasion mechanisms adopted by the virus, and the speculated role of antibody dependent enhancement (ADE) in coronavirus disease 2019 (COVID-19) pathogenesis will aid in identifying and designing effective therapeutics.

Aim: This review aims to provide an in-depth view of the current knowledge available on the range of host defense mechanisms activated by SARS-CoV-2 infection and various immune evasion mechanisms utilized by the virus. In addition, it also highlights the postulated role of ADE in viral pathogenesis and covers the different preventive and therapeutic options available for the treatment of COVID-19 based on current literature.

Discussion: The ongoing COVID-19 pandemic serves as a timely reminder on the constant evolutionary process the virus undergoes to emerge as a novel strain and to spread undetected within the population. Similar to other infectious diseases, the host defence mechanism is triggered, and it plays a central role in dampening viral replication by recruiting immune cells and activating anti-viral mechanisms to control the spread of infection by SARS-CoV-2. However, the virus has adopted different immune evasion mechanisms to circumvent host surveillance to successfully establish infection. Hence, understanding the host’s immune responses triggered by SARS-CoV-2 infection is critical for identifying and designing novel and effective therapeutics. Currently, over 70% of the population are either asymptomatic or they showcase mild to moderate symptoms and reasons for why some people can mount immune responses more quickly than others are unknown. However, a growing body of research speculates that the ADE mechanism may facilitate the SARS-CoV-2 entry and can contribute to severe clinical manifestations. With the constant rise in the number of confirmed cases, there is an immediate need for an effective vaccine to mitigate the spread of the virus. Presently, there is no treatment for COVID-19 although several vaccine candidates are in clinical trials. Therefore, preventive measures like social distancing, isolation, and travel restrictions, may be the key to controlling the rapid spread of COVID-19.

Antibody-dependent enhancement, Coronavirus, COVID-19, SARS-CoV-2, treatment, type 1 interferon.

Article Details

How to Cite
Eswaran, N., & Krishna, S. (2020). Coronavirus Disease 2019 (COVID-19): Pathogenesis, Immune Responses, and Treatment Options. Asian Journal of Research in Infectious Diseases, 5(1).
Review Article


WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]; 2020.

Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. Lancet Publishing Group. 2020;395:514–23.

Liaw CWJ, Lim ASE, Koh WHV, Loh JP, Kan C, Chan KW, et al. Epidemiology of the four human coronaviruses 229E, HKU1, NL63 and OC43 detected over 30 months in the Singapore military. Int J Infect Dis. Elsevier BV. 2012;16:135.

Shi T, Arnott A, Semogas I, Falsey AR, Openshaw P, Wedzicha JA, et al. The Role of Common Respiratory Viruses in ARI in Older Adults • JID 2019:XX (XX XXXX)• S1 The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. Lancet Publishing Group. 2020;395:497–506. DOI:10.1016/S0140-6736(20)30183-5

Hoffmann M, Kleine-Weber H, Schroeder S, Mü MA, Drosten C, Pö S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.

Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis virus transmission pathways. J Pathol. John Wiley & Sons, Ltd. 2004;203:622–30.

Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA - J. Am. Med. Assoc. American Medical Association. 2020;707–8.

Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value and transmission of 2019-nCoV. Int. J. Oral Sci. Springer Nature. 2020;1–6.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. Massachussetts Medical Society. 2020;382:1708–20.

Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med. American College of Physicians. 2020;172:577–82.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. Massachussetts Medical Society. 2020;1199–207.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. Lancet Publishing Group. 2020;395:507–13.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. American Society for Clinical Investigation. 2020;130:2620–9.

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. Massachussetts Medical Society. 2020;1177–9.

Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci. Korean Academy of Medical Science. 2020;35.

Pan Y, Zhang D, Yang P, M Poon LL, Wang Q. Viral load of SARS-CoV-2 in clinical samples; 2020.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. American Medical Association. 2020;323:1061–9.

Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. Xi’an Jiaotong University. 2020;102–8.

Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. NLM (Medline). 2020;337–42.

Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. John Wiley & Sons, Ltd. 2004;136:95–103.

Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. NLM (Medline). 2020;48:008.

Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.02.26.20028191. DOI:10.1101/2020.02.26.20028191

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.02.23.20026690.

Prompetchara E, Ketloy C, Palaga T. Allergy and Immunology Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. Springer Nature. 2020;533–5.

Wang C, Xia CQ. The Involvement of Natural Killer Cells in the Pathogenesis of Severe Acute Respiratory Syndrome. Am J Clin Pathol. American Society of Clinical Pathologists. 2004;121:507–11.

Braud VM, Allan DSJ, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. Nature Publishing Group. 1998;391:795–9.

Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity. Cell Press. 2019;907–23.

De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. Nature Publishing Group. 2016;523–34.

Lu X, Pan J, Tao J, Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes. Nature Publishing Group. 2011;42:37–45.

Wang SF, Chen KH, Chen M, Li WY, Chen YJ, Tsao CH, et al. Human-Leukocyte Antigen Class I Cw 1502 and Class II DR 0301 Genotypes Are Associated with Resistance to Severe Acute Respiratory Syndrome (SARS) Infection. Viral Immunol. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA. 2011;24:421–6.

Keicho N, Itoyama S, Kashiwase K, Phi NC, Long HT, Ha LD, et al. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum Immunol. Elsevier. 2009;70:527–31.

Hajeer AH, Balkhy H, Johani S, Yousef MZ, Arabi Y. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Ann Thorac Med. Medknow Publications. 2016;11:211–3.

Yang Z, Wang S, Li Q, Li Y, Wei M, Gao H, et al. Determining SARS sub-clinical infection: A longitudinal seroepidemiological study in recovered SARS patients and controls after an outbreak in a general hospital. Scand J Infect Dis. 2009;41:507–10.

Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. Elsevier. 2014;44:528–32.

Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. Blackwell Publishing Ltd. 2004;10:1062–6.

Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.03.24.20042382.

Tang F, Quan Y, Xin Z-T, Wrammert J, Ma M-J, Lv H, et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study. J Immunol. The American Association of Immunologists. 2011;186:7264–8. DOI:10.4049/jimmunol.0903490

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) | Clinical Infectious Diseases | Oxford Academic [Internet]; 2020.

Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect. Dis. Elsevier. 2009;291–300.

Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. Academic Press Inc. 2016;219–43.

Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, et al. Distinct immune response in two MERS-CoV-infected patients: Can we go from bench to bedside? PLoS One. Public Library of Science. 2014;9:88716.

Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J Cell Physiol. Wiley-Liss Inc. 2019;234:2143–51.

Totura AL, Baric RS. SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon. Curr. Opin. Virol. Elsevier. 2012;264–75.

Freundt EC, Yu L, Park E, Lenardo MJ, Xu X-N. Molecular Determinants for Subcellular Localization of the Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame 3b Protein. J Virol. American Society for Microbiology. 2009;83:6631–40.

Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. Springer. 2013;1445–59.

Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue hemorrhagic fever in infants: Research opportunities ignored. Emerg. Infect. Dis. Centers for Disease Control and Prevention (CDC). 2002;1474–9.

Lv H, Wu NC, Tak-Yin Tsang O, Malik Peiris J, Wilson IA, Mok CK, et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections ll Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. CellReports. 2020;31:107725.

Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. American Society for Microbiology. 2019;94:2015–34.

Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, et al. Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent Fc R Pathway. J Virol. American Society for Microbiology. 2011;85:10582–97.

Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19.

Yuan FF, Tanner J, Chan PKS, Biffin S, Dyer WB, Geczy AF, et al. Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome. Tissue Antigens. John Wiley & Sons, Ltd. 2005;66:291–6.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. Springer. 2020;846–8.

Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. J Med Virol. John Wiley and Sons Inc. 2020;92:791–6.

Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:203–8. DOI:10.3760/cma.j.issn.1001-0939.2020.0005

Sun D, Li H, Lu X-X, Xiao H, Ren J, Fu •, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr. 2020;16:251–9.

Shimizu M. Clinical Features of Cytokine Storm Syndrome. Cytokine Storm Syndr. Springer International Publishing. 2019;31–41.

Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin. Exp. Rheumatol. NLM (Medline). 2020;175–80. Available:

Xu Z, Shi L, Zhang J, Huang L, Zhang C, Liu Bsc H, et al. Case Report Pathological findings of COVID-19 associated with acute respiratory distress syndrome. 2020;8.

Haydar D, Cory TJ, Birket SE, Murphy BS, Pennypacker KR, Sinai AP, et al. Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways. J Immunol. The American Association of Immunologists. 2019;203:1021–30.

Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest. American College of Chest Physicians. 2012;141:1153–9.

Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol. Elsevier Inc. 2020;36:948–51.

Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. American Society for Microbiology. 2018;9:221–39.

Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. American Society for Biochemistry and Molecular Biology Inc. 2020;4773–9.

Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed Initiation of Remdesivir in a COVID‐19‐Positive Patient. Pharmacother J Hum Pharmacol Drug Ther. Pharmacotherapy Publications Inc. 2020;40:592–8.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. 2020;395:2020.

Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: A review. Ther. Clin. Risk Manag. Dove Press. 2008;1023–33.

Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59:252–6.

Peiris J, Yuen K, Chan Lai CM Chu E Tsui CY Tam MML Wong MW Tse TL Que JSM Peiris J Sung VCW Wong KS. EXPEDITED ORIGINAL ARTICLE Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J; 2003.

Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J virus Erad. Mediscript. 2020;6:45–51.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. Elsevier Ltd; 2020.

DRAFT landscape of COVID-19 candidate vaccines – 20 August 2020 [Internet]. [cited 2020 Jul 8].

Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Nature Research. 2020;579:270–3.

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. Taylor and Francis Ltd. 2020;382–5.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. Springer Nature. 2020;17:613–20.

Yang Y, Shen C, Li J, Yuan J, Yang M, Wang F, et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2019:2020.03.02.20029975.

Cron RQ, Chatham WW. The Rheumatologist’s Role in COVID-19. J. Rheumatol. NLM (Medline). 2020;639–42.

Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin. Immunol. Academic Press Inc. 2020;108448.

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. [Internet]. [cited 2020 Jul 20].

Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, et al. Journal Pre-proof Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy. Int J Infect Dis; 2020.